EP4408528A1 - Cosmetic composition comprising cranberry extract and cranberry seed oil - Google Patents
Cosmetic composition comprising cranberry extract and cranberry seed oilInfo
- Publication number
- EP4408528A1 EP4408528A1 EP22799871.3A EP22799871A EP4408528A1 EP 4408528 A1 EP4408528 A1 EP 4408528A1 EP 22799871 A EP22799871 A EP 22799871A EP 4408528 A1 EP4408528 A1 EP 4408528A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cranberry
- cosmetic composition
- seed oil
- extract
- scalp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000020237 cranberry extract Nutrition 0.000 title claims abstract description 72
- 239000002537 cosmetic Substances 0.000 title claims abstract description 67
- 239000010638 cranberry seed oil Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000000699 topical effect Effects 0.000 claims abstract description 9
- 210000004761 scalp Anatomy 0.000 claims description 32
- 206010061218 Inflammation Diseases 0.000 claims description 20
- 230000004054 inflammatory process Effects 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 10
- 239000001506 calcium phosphate Substances 0.000 claims description 9
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 9
- 239000000347 magnesium hydroxide Substances 0.000 claims description 9
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 9
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 9
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 9
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 9
- 150000007524 organic acids Chemical class 0.000 claims description 8
- 235000005985 organic acids Nutrition 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 241000195940 Bryophyta Species 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 241001303601 Rosacea Species 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 235000011929 mousse Nutrition 0.000 claims description 4
- 201000004700 rosacea Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010016936 Folliculitis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 230000037307 sensitive skin Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 28
- 240000001717 Vaccinium macrocarpon Species 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 102100040247 Tumor necrosis factor Human genes 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- -1 phenolic acids Chemical class 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 12
- 235000004634 cranberry Nutrition 0.000 description 12
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 11
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 11
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 235000021019 cranberries Nutrition 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000000944 Soxhlet extraction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical class CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 238000012311 Shapiro-Wilk normality test Methods 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021060 food property Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003751 hair shininess Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Definitions
- the present invention relates to a cosmetic composition for topical use, comprising a combination of cranberry extract and cranberry seed oil.
- the invention is concerned with a cosmetic composition for topical use, comprising a combination of cranberry extract and cranberry seed oil, wherein the cranberry extract and the cranberry seed oil are in a ratio between about 15:1 to about 1 :0.5.
- the invention also relates to a cosmetic product comprising the cosmetic composition comprising cranberry extract in combination with cranberry seed oil as defined herein, as well as to a method for alleviating the symptoms of inflammation of the human skin or the human scalp, comprising topically applying to the skin or the scalp the cosmetic composition or the cosmetic product as defined herein.
- the invention is also concerned with the use of the cosmetic composition or the cosmetic product as defined herein in alleviating the symptoms of inflammation of the human skin or the human scalp.
- Cranberries (Vaccinium macrocarpori) contain large quantities of antioxidants, vitamins, minerals and phenolic compounds, which prompted their increasing use in various food products and nutraceutical supplements. Extracts from cranberries have also been used in a number of cosmetics, due to their anti-glycation, anti-microbial, antioxidant and anti-aging properties.
- Cranberry seed oil provides a distinct combination of omega-3, omega-6 and omega-9 fatty acids, as well as tocopherols, tocotrienols and a high concentration of antioxidants.
- the oil has been used in a number of cosmetics, due to its moisturizing, nourishing, anti-aging, antioxidant, anti-microbial, UV protecting, anti-irritant, and skin-lightening properties.
- Skin inflammation in an interdependent relationship with oxidative stress, can manifest itself in a number of ways, such as redness, breakouts, acne, blemishes, rosacea, dark spots, hyperpigmentation, eczema, itching, or swelling, among others. Inflammation of the scalp, although harder to identify, can be observed as flakiness, swelling or redness of the scalp.
- compositions containing natural and/or upcycled ingredients that have a soothing effect on the human skin or scalp (i.e. that can reduce or alleviate the symptoms of skin or scalp inflammation), in particular compositions based on cranberry components.
- the invention provides a cosmetic composition for topical use, comprising a cranberry extract in combination with cranberry seed oil.
- a cosmetic product comprising a cosmetic composition for topical use, comprising cranberry extract in combination with cranberry seed oil as defined herein and a cosmetically acceptable base is provided.
- the invention further provides a method, in particular a cosmetic method, for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, comprising applying to the skin or the scalp a cosmetic composition or a cosmetic product as defined herein.
- a cosmetic composition or a cosmetic product as defined herein in alleviating or removing the symptoms of inflammation of the human skin or the human scalp is provided.
- Figure 1 shows a non-parametric statistical analysis using a Mann Whitney test for TNF-a quantification in samples of culture cells treated with cranberry extract, cranberry seed oil and combinations of cranberry extract and cranberry seed oil, respectively, compared with a sample treated with a reference (dexamethasone).
- a combination of cranberry extract and cranberry seed oil showed synergistic anti-inflammatory activity by significantly reducing the release of cytokine TNF- a by keratinocytes stressed with phorbol 12-myristate 13-acetate (PMA).
- PMA phorbol 12-myristate 13-acetate
- the invention therefore, provides a cosmetic composition for topical use, comprising a combination of cranberry extract and cranberry seed oil.
- the cranberries from which both the cranberry extract and cranberry seed oil are obtained may be sourced from the United States, for example.
- the cranberry extract is obtained from Vaccinium macrocarpon berries and, preferably, from the juice obtained by crushing them.
- the cranberry extract can be obtained by a process of extraction from cranberry fruit. After harvesting, drying and grinding, the cranberries may be contacted with a solvent that has an affinity for the desired components to be extracted. Subsequently, a filtration step may separate the solvent in which the desired components are dissolved from the cranberry solid matrix, providing a native extract. The solvent may then be removed, for example evaporated, in order to concentrate the filtrate. The resulting native extract may be subjected to further processing by separation, purification and/or further formulation. Suitable methods of extraction include ultrasound, microwave-assisted or Soxhlet extraction. The solvents that may be used in the extraction process may be hydrophilic or lipophilic. Depending on the solvent used, the cranberry extract may be called a “hydrophilic extract” or a “lipophilic extract”.
- the cranberry extract is a hydrophilic extract.
- hydrophilic solvents examples include, but are not limited to, water; alcohols, such as methanol, ethanol, propanols (normal or iso-), butanols (normal, iso- or tert-); ketones, such as acetone; nitriles, such as acetonitrile; or mixtures thereof.
- acids such as hydrochloric or sulfuric acid, or organic acids such as trichloroacetic, trifluoroacetic, formic, citric or acetic acid, or mixtures thereof may be used to facilitate the extraction.
- the cranberry extract is an upcycled product obtained after partial extraction of the polyphenols from cranberry juice.
- the cranberry extract comprises organic acids, such as phenolic acids, especially those derived from hydroxybenzoic and hydroxycinnamic acid, quinic, malic, shikimic, and citric acid.
- organic acids such as phenolic acids, especially those derived from hydroxybenzoic and hydroxycinnamic acid, quinic, malic, shikimic, and citric acid.
- the solvent employed to extract the desired components may be a water- ethanol mixture.
- the cranberry extract may contain between about 7% to about 30% w/w of organic acids.
- the cranberry extract may contain about 7%, about 18% or about 30% organic acids by weight of the extract.
- the cranberry extract contains more than about 30% organic acids by weight of the extract.
- the cranberry extract may be further mixed with an additive.
- Additives are substances added to natural extracts to maintain or improve their stability, texture, or appearance.
- the additive may be selected from the group consisting of sodium benzoate, potassium sorbate, magnesium hydroxide, tricalcium phosphate, glycerine and mixtures thereof. Their role is to stabilize the pH of the cranberry extract.
- the additive may be magnesium hydroxide.
- the cranberry extract may contain a further additive, such as tricalcium phosphate.
- the cranberry extract may contain about 10% w/w magnesium hydroxide.
- the cranberry extract may contain less than about 1 % w/w of tricalcium phosphate.
- the cranberry extract may contain about 10% w/w magnesium hydroxide and less than about 1 % w/w of tricalcium phosphate.
- the cranberry extract may be in any suitable form, for example in a liquid or powder form.
- the cranberry extract may undergo further processing, such as drying.
- an additive may be added to the cranberry extract prior to the drying step.
- the cranberry extract may be obtained by a process as described herein.
- the cranberry fruit may be ground, extracted with a mixture of water and ethanol and then filtered.
- the filter cake may be discarded and the solvent may be removed from the filtrate, for example by concentration in order to obtain a native extract of cranberry.
- the native extract may be further processed by removing a polyphenols-rich fraction.
- the fraction left after removal of the polyphenol-rich fraction may be mixed with magnesium hydroxide and/or tricalcium phosphate, the mixture may be dried, e.g. by spray drying, and, optionally, it may further undergo sieving.
- the cranberry seed oil possesses a distinct combination of omega-3 fatty acids (about 26% to 34% w/w), omega-6 (about 32% to 42% w/w) and omega-9 (about 18% to 30% w/w), as well as tocopherols, tocotrienols and antioxidants.
- a number of extraction techniques such as solvent, ultrasonic-assisted, super-critical fluid, Soxhlet extraction or mechanical pressing, may be used to extract the cranberry seed oil.
- the cranberry seed oil is obtained by cold pressing, resulting in virgin (i.e. an oil produced by only physical or mechanical means) cranberry seed oil.
- the cranberry seed oil may be a virgin cranberry seed oil.
- the cranberry seed oil may be obtained by a process as described herein.
- the seeds removed from the fruit may be cold pressed and filtered.
- the filtration cake may be discarded and the filtrate (i.e. the virgin cranberry seed oil) may be used as is.
- the ratio between the cranberry extract and cranberry seed oil is between about 15:1 to about 1 :0.2.
- the ratio between the cranberry extract and cranberry seed oil is between about 12:1 to about 1 :0.5.
- the ratio between the cranberry extract and cranberry seed oil may be about 12:1 , 11 :1 , 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1 :1 , 1 :0.9, 1 :0.8, 1 :0.7, 1 :0.6 or 1 :0.5, in particular about 10:1 or about 1 :1.
- a cosmetic product comprising a cosmetic composition comprising cranberry extract in combination with cranberry seed oil as defined hereinbefore and a cosmetic base.
- the cosmetic base may comprise any cosmetically acceptable excipient.
- a cosmetically acceptable excipient can be any excipient commonly used in the preparation of cosmetic preparations for use on the human skin or scalp. Suitable excipients include, but are not limited to, ingredients that can influence organoleptic properties and penetration of the skin, as well as the amount of time the active ingredient(s) remain active on the skin.
- liquids such as water, oils or surfactants, including those of petroleum, animal, plant or synthetic origin, such as and not restricted to, peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbates, sorbitan esters, ether sulfates, sulfates, betaines, glycosides, maltosides, fatty alcohols, nonoxynols, poloxamers, polyoxyethylenes, polyethylene glycols, dextrose, glycerol, digitonin, and the like, or combinations thereof.
- oils or surfactants including those of petroleum, animal, plant or synthetic origin, such as and not restricted to, peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbates, sorbitan esters, ether sulfates, sulfates, betaines, glycosides, maltosides, fatty alcohols, nonoxynols, poloxamers, polyoxyethylenes, polyethylene glycols, dextrose,
- the formulation for topical application to the skin may take any physical form.
- the cosmetic product may be in the form of a liposome, mixed liposomes, oleosomes, niosomes, ethosomes, milliparticles, microparticles, nanoparticles and solid-lipid nanoparticles, vesicles, micelles, mixed micelles of surfactants, surfactant-phospholipid mixed micelles, millispheres, microspheres and nanospheres, lipospheres, millicapsules, microcapsules and nanocapsules, as well as microemulsions and nanoemulsions, which can be added to achieve a greater penetration of the cosmetic composition as defined herein.
- the cosmetic product may be produced in any solid, liquid, or semi-solid form useful for application to the skin topically or by transdermal application.
- these preparations of topical or transdermal application include, but are not restricted to, creams, multiple emulsions, such as and not restricted to, oil and/or silicone in water emulsions, water-in-oil and/or silicone emulsions, water/oil/water or water/silicone/water type emulsions, and oil/water/oil or silicone/water/silicone type emulsions, micro-emulsions, emulsions and/or solutions, liquid crystals, anhydrous compositions, aqueous dispersions, oils, milks, balsams, foams, aqueous or oily lotions, aqueous or oily gels, cream, hydro-alcoholic solutions, hydro-glycolic solutions, hydrogels, liniments, sera, soaps, face masks, serums, polysaccharide films, o
- the cosmetic product of the present invention may also be any product typically used for hair care, including but not limited to a shampoo, conditioner, spray, treatment, mask, strengthened preshampoo, lotion, serum, cream, foam, mousse, and gel.
- the cosmetic product is a shampoo, anti-frizz hair spray, beauty hair mask, hair shininess serum, hair conditioner, hair strengthener pre-shampoo, or hair protection lotion. Both leave-on and rinse-off product types are suitable.
- the cosmetic product according to the present invention may further comprise one or more materials selected from the group consisting of carriers, solvents, surfactants, thickeners, styling polymers, anti-dandruff actives, antimicrobial materials, skin and scalp actives, vitamins, salts, buffers, hair growth agents, conditioning materials, hair-fixative polymers, fragrances, colorings/colorants, dyes, pigments, opacifiers, pearlescent aids, oils, waxes, preservatives, sensates, sunscreens, medicinal agents, antifoaming agents, antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, film formers or materials, pH adjusters, propellants, oxidizing agents, and reducing agents.
- carriers solvents, surfactants, thickeners, styling polymers, anti-dandruff actives, antimicrobial materials, skin and scalp actives
- the cosmetic product of the present invention may be produced in any form typically used for skin or scalp care, including but not limited to a cream, a lotion, a spray, a gel, a foam a stick, a shampoo, a conditioner or a mousse, preferably a cream or a gel.
- the cosmetic compositions and products of the present invention can additionally further comprise any suitable optional ingredients as desired.
- Such optional ingredients should be physically and chemically compatible with the essential components of the cosmetic composition or cosmetic product, and should not otherwise unduly impair stability, aesthetics or performance.
- CTFA Cosmetic Ingredient Handbook Tenth Edition (published by the Cosmetic, Toiletry, and Fragrance Association, Inc., Washington D.C.) (2004) describes a wide variety of non-limiting materials that can be added to the compositions and products of the present invention.
- the concentration of the cranberry extract in a topical formulation of a cosmetic composition can be up to about 30% w/w.
- the cosmetic product comprises about 0.5% to about 30%, optionally about 1 % to about 25%, optionally about 5% to about 15% w/w of cranberry extract.
- the cranberry extract may be provided in powder form and may be mixed with a solvent such as water, ethanol/water or glycerine, before incorporation in a cosmetic product.
- a solvent such as water, ethanol/water or glycerine
- the concentration of the cranberry seed oil in a topical formulation of a cosmetic product can be up to about 10% w/w.
- the cosmetic product comprises about 0.05% to about 10%, optionally about 0.5% to about 5%, optionally about 1 % to about 3% w/w of cranberry seed oil.
- the invention further provides a method for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, comprising topically applying to the skin or the scalp a composition comprising cranberry extract in combination with cranberry seed oil or a cosmetic product comprising a composition comprising cranberry extract in combination with cranberry seed oil as defined hereinbefore.
- the invention provides a cosmetic method for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, i.e. a non-therapeutic method.
- the inflammation of the human skin or the human scalp may be caused by an infection, by an allergic reaction or by exposure to UV radiation.
- the inflammation of the human skin may be selected from the group consisting of sensitive skin, irritated skin, atopic dermatitis, rosacea, eczema and psoriasis.
- the inflammation of the human scalp may be selected from the group consisting of dermatitis, such as irritated skin due to dryness, itchy scalp, seborrhoeic dermatitis and contact dermatitis, scalp folliculitis and psoriasis of the scalp.
- dermatitis such as irritated skin due to dryness, itchy scalp, seborrhoeic dermatitis and contact dermatitis, scalp folliculitis and psoriasis of the scalp.
- Non-limiting examples of symptoms of inflammation include redness, breakouts, acne, blemishes, rosacea, dark spots, hyperpigmentation, eczema, itching, or swelling of the skin and flakiness, swelling or redness of the scalp.
- composition comprising cranberry extract in combination with cranberry seed oil or a cosmetic product comprising a composition comprising cranberry extract in combination with cranberry seed oil as defined hereinbefore in alleviating or removing the symptoms of inflammation of the human skin or the human scalp is provided.
- the invention provides a cosmetic use for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, i.e. a non-therapeutic use.
- the cranberry fruit may be ground, extracted with a mixture of water and ethanol and filtered.
- the filter cake may be discarded and the filtrate may undergo concentration/desolventation in order to obtain a native extract of cranberry.
- the resulting native extract is further subjected to separation, purification and further formulation by mixing with magnesium hydroxide and tricalcium phosphate.
- the mixture may be dried by spray drying and, optionally, it may further undergo sieving.
- cranberries were ground and extracted with 80 kg of water.
- the liquid was separated from the solid mass, concentrated and subjected to further processing, comprising the step of mixing with magnesium hydroxide (8 kg) and tricalcium phosphate (1 Kg). 92 kg of cranberry extract with 30% w/w organic acids was obtained.
- Example 2 Process of production of a cranberry seed oil
- the seeds removed from the fruit may be cold pressed and filtered.
- the filtration cake may be discarded and the filtrate (i.e. the virgin cranberry seed oil) may be used as is.
- the filtrate i.e. the virgin cranberry seed oil
- 1 .667 kg of cranberries were squeezed and sliced to remove the seeds.
- the seeds (about 17 g) were collected, dried and cold pressed to obtain about 1 g of cranberry seed oil.
- Example 3 Anti-inflammatory effect of a cranberry extract, a cranberry seed oil and combinations of a cranberry extract and a cranberry seed oil
- a cranberry extract, a cranberry seed oil and combinations of a cranberry extract and a cranberry seed oil on the anti-inflammatory activity of keratinocytes stressed with PMA was evaluated by comparing the decrease of the cytokine TNF-a release of Normal Human Epidermal Keratinocytes (NHEKs) treated with the cranberry products and stressed with PMA (Phorbol 12- myristate 13-acetate) with the TNF-a release of untreated NHEKs stressed with PMA.
- NHEKs Normal Human Epidermal Keratinocytes
- the cell culture was done on primary cells isolated from fresh biopsies. NHEKs were seeded in a type I collagen pre-coated 24 wells-plate at 30 000 cells per well in triplicate.
- the cells were incubated 24 hours in complete medium (Epilife medium supplemented with HKGS, Gibco) and 1 % of antibiotics (Sigma-Aldrich) at 37 °C with 5% CO 2 .
- the cells were rinsed twice with phosphate buffered saline (PBS, Gibco) and pre-incubated with active components for 24 hours in Epilife complete medium (Epilife + Human keratinocyte growth supplements (HKGS) supplements, Gibco) without Hydrocortisone and 1 % of antibiotics at 37 °C with 5% CO 2 .
- PMA Phorbol 12-myristate 13- acetate, Sigma
- Non-treated cells were used as a blank.
- Cells treated with a known anti-inflammatory were used as a reference.
- the cell media were collected and centrifuged at 2000 g for 10 minutes at 4 °C to eliminate dead cells.
- the media were stored at -20 °C.
- a MTT assay was performed to evaluate treatments toxicity and for the normalisation of TNF-a quantification.
- the assay was done in quadruplicate.
- MTT assay MTT solution (Sigma) diluted at 1 mg/mL in basal medium was added to each well and incubated for 3 hours at 37 °C, 5% CO 2 . Then, the medium was removed and 300 pL of dimethyl sulfoxide (DMSO, Sigma) was added into each well to dissolve the formazan crystals. Homogenization was done under orbital agitation for few minutes. The optical density was measured at a wavelength of 560 nm.
- DMSO dimethyl sulfoxide
- TNF-a quantification was realized with the Human TNF-alpha Quantikine ELISA kit (DTA00D, R&D Systems).
- the Four Parameter Logistic Curve analysis was performed via the Myassays website (http://myassays.com) after subtraction of optical density at 450 nm by optical density at 540 nm.
- the quantification was normalized with the optical density measured via the MTT assay.
- Figure 1 shows the results of the non-parametric statistical analysis using the Mann Whitney test for samples 1 to 7 in Table 1 .
- the cranberry extract at 0.5 mg/mL (entry 3), the cranberry seed oil at 0.05% v/v (entry 4) and 0.005% v/v (entry 5) significantly reduced the TNF-a release by 16%*, 34%*** and 32%***, respectively, compared to the sample of entry 1 .
- a combination of cranberry extract and cranberry seed oil has synergistic anti-inflammatory capability compared to each of the cranberry extract and cranberry seed oil independently.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a cosmetic composition for topical use, comprising cranberry extract in combination with cranberry seed oil.
Description
COSMETIC COMPOSITION COMPRISING CRANBERRY EXTRACT AND CRANBERRY SEED OIL
The present invention relates to a cosmetic composition for topical use, comprising a combination of cranberry extract and cranberry seed oil. In particular, the invention is concerned with a cosmetic composition for topical use, comprising a combination of cranberry extract and cranberry seed oil, wherein the cranberry extract and the cranberry seed oil are in a ratio between about 15:1 to about 1 :0.5. The invention also relates to a cosmetic product comprising the cosmetic composition comprising cranberry extract in combination with cranberry seed oil as defined herein, as well as to a method for alleviating the symptoms of inflammation of the human skin or the human scalp, comprising topically applying to the skin or the scalp the cosmetic composition or the cosmetic product as defined herein. The invention is also concerned with the use of the cosmetic composition or the cosmetic product as defined herein in alleviating the symptoms of inflammation of the human skin or the human scalp.
BACKGROUND
Cranberries (Vaccinium macrocarpori) contain large quantities of antioxidants, vitamins, minerals and phenolic compounds, which prompted their increasing use in various food products and nutraceutical supplements. Extracts from cranberries have also been used in a number of cosmetics, due to their anti-glycation, anti-microbial, antioxidant and anti-aging properties.
The seeds, separated from the fruit, are the source of cranberry seed oil. Cranberry seed oil provides a distinct combination of omega-3, omega-6 and omega-9 fatty acids, as well as tocopherols, tocotrienols and a high concentration of antioxidants. The oil has been used in a number of cosmetics, due to its moisturizing, nourishing, anti-aging, antioxidant, anti-microbial, UV protecting, anti-irritant, and skin-lightening properties.
Skin inflammation, in an interdependent relationship with oxidative stress, can manifest itself in a number of ways, such as redness, breakouts, acne, blemishes, rosacea, dark spots, hyperpigmentation, eczema, itching, or swelling, among others. Inflammation of the scalp, although harder to identify, can be observed as flakiness, swelling or redness of the scalp.
In order to counteract the unpleasant feel and appearance of skin and scalp inflammation, commercial soothing compositions have been marketed. Of these compositions, those containing natural extracts have become more popular in recent years. Most natural soothing compositions contain extracts from arnica, aloe vera, calendula, chamomile (containing bisabolol), coconut oil, green tea, oatmeal, shea butter and tea tree oil, for example.
Although not as widely used as the above-mentioned ingredients, cranberry extracts have also been shown to have skin and scalp soothing properties. It is believed that the high concentration of cranberry polyphenols is responsible for such effects.
There is still a need to provide compositions containing natural and/or upcycled ingredients that have a soothing effect on the human skin or scalp (i.e. that can reduce or alleviate the symptoms of skin or scalp inflammation), in particular compositions based on cranberry components.
SUMMARY OF THE INVENTION
In a first aspect, the invention provides a cosmetic composition for topical use, comprising a cranberry extract in combination with cranberry seed oil.
In a further aspect, a cosmetic product comprising a cosmetic composition for topical use, comprising cranberry extract in combination with cranberry seed oil as defined herein and a cosmetically acceptable base is provided.
The invention further provides a method, in particular a cosmetic method, for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, comprising applying to the skin or the scalp a cosmetic composition or a cosmetic product as defined herein.
In yet another aspect, use of a cosmetic composition or a cosmetic product as defined herein in alleviating or removing the symptoms of inflammation of the human skin or the human scalp is provided.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a non-parametric statistical analysis using a Mann Whitney test for TNF-a quantification in samples of culture cells treated with cranberry extract, cranberry seed oil and combinations of cranberry extract and cranberry seed oil, respectively, compared with a sample treated with a reference (dexamethasone).
DETAILED DESCRIPTION
Preferred and/or optional features of the invention will now be set out. Any aspect of the invention may be combined with any other aspect of the invention unless the context demands otherwise. Any of the preferred or optional features of any aspect may be combined, singly or in combination, with any aspect of the invention, as well as with any other preferred or optional features, unless the context demands otherwise.
Cosmetic Composition
It has surprisingly been found that a combination of cranberry extract and cranberry seed oil showed synergistic anti-inflammatory activity by significantly reducing the release of cytokine TNF- a by keratinocytes stressed with phorbol 12-myristate 13-acetate (PMA). In particular, it was found that the TNF-a release was not only significantly reduced when a combination of cranberry extract and cranberry seed oil was employed compared to when each of the cranberry extract and the cranberry seed oil were employed independently, but also it was much lower than the TNF-a release expected by adding the effects of the two independent components.
The invention, therefore, provides a cosmetic composition for topical use, comprising a combination of cranberry extract and cranberry seed oil.
The cranberries from which both the cranberry extract and cranberry seed oil are obtained may be sourced from the United States, for example.
Cranberry Extract
The cranberry extract is obtained from Vaccinium macrocarpon berries and, preferably, from the juice obtained by crushing them.
For example, the cranberry extract can be obtained by a process of extraction from cranberry fruit. After harvesting, drying and grinding, the cranberries may be contacted with a solvent that has an affinity for the desired components to be extracted. Subsequently, a filtration step may separate the solvent in which the desired components are dissolved from the cranberry solid matrix, providing a native extract. The solvent may then be removed, for example evaporated, in order to concentrate the filtrate. The resulting native extract may be subjected to further processing by separation, purification and/or further formulation. Suitable methods of extraction include ultrasound, microwave-assisted or Soxhlet extraction.
The solvents that may be used in the extraction process may be hydrophilic or lipophilic. Depending on the solvent used, the cranberry extract may be called a “hydrophilic extract” or a “lipophilic extract”.
In an embodiment, the cranberry extract is a hydrophilic extract.
Examples of suitable hydrophilic solvents that may be used in the extraction process include, but are not limited to, water; alcohols, such as methanol, ethanol, propanols (normal or iso-), butanols (normal, iso- or tert-); ketones, such as acetone; nitriles, such as acetonitrile; or mixtures thereof. Optionally, acids, such as hydrochloric or sulfuric acid, or organic acids such as trichloroacetic, trifluoroacetic, formic, citric or acetic acid, or mixtures thereof may be used to facilitate the extraction.
In one embodiment, the cranberry extract is an upcycled product obtained after partial extraction of the polyphenols from cranberry juice.
In an embodiment, the cranberry extract comprises organic acids, such as phenolic acids, especially those derived from hydroxybenzoic and hydroxycinnamic acid, quinic, malic, shikimic, and citric acid.
In an embodiment, the solvent employed to extract the desired components may be a water- ethanol mixture.
In an embodiment, the cranberry extract may contain between about 7% to about 30% w/w of organic acids. For instance, the cranberry extract may contain about 7%, about 18% or about 30% organic acids by weight of the extract.
It has been shown that polyphenolic plant sources possess antioxidant activity and could potentially prevent and control oxidative stress and its effects (Silva Caldas, A.P., International Journal of Food Properties, 2018, 21, 582-592, the disclosure of which is herein incorporated by reference). Therefore, it is advantageous to use a cranberry extract with a higher content of organic acids, such as phenolic acids.
Therefore, in one embodiment, the cranberry extract contains more than about 30% organic acids by weight of the extract.
Optionally, the cranberry extract may be further mixed with an additive. Additives are substances added to natural extracts to maintain or improve their stability, texture, or appearance.
For example, the additive may be selected from the group consisting of sodium benzoate, potassium sorbate, magnesium hydroxide, tricalcium phosphate, glycerine and mixtures thereof. Their role is to stabilize the pH of the cranberry extract.
In one embodiment, the additive may be magnesium hydroxide. Optionally, the cranberry extract may contain a further additive, such as tricalcium phosphate.
In one embodiment, the cranberry extract may contain about 10% w/w magnesium hydroxide.
In one embodiment, the cranberry extract may contain less than about 1 % w/w of tricalcium phosphate.
In one embodiment, the cranberry extract may contain about 10% w/w magnesium hydroxide and less than about 1 % w/w of tricalcium phosphate.
The cranberry extract may be in any suitable form, for example in a liquid or powder form.
In an embodiment, the cranberry extract may undergo further processing, such as drying. Optionally, an additive may be added to the cranberry extract prior to the drying step.
For example, the cranberry extract may be obtained by a process as described herein. The cranberry fruit may be ground, extracted with a mixture of water and ethanol and then filtered. The filter cake may be discarded and the solvent may be removed from the filtrate, for example by concentration in order to obtain a native extract of cranberry. The native extract may be further processed by removing a polyphenols-rich fraction. The fraction left after removal of the polyphenol-rich fraction may be mixed with magnesium hydroxide and/or tricalcium phosphate, the mixture may be dried, e.g. by spray drying, and, optionally, it may further undergo sieving.
Cranberry seed oil
The cranberry seed oil possesses a distinct combination of omega-3 fatty acids (about 26% to 34% w/w), omega-6 (about 32% to 42% w/w) and omega-9 (about 18% to 30% w/w), as well as tocopherols, tocotrienols and antioxidants.
A number of extraction techniques, such as solvent, ultrasonic-assisted, super-critical fluid, Soxhlet extraction or mechanical pressing, may be used to extract the cranberry seed oil.
Because some compounds found in cranberry seed oil may be destroyed or removed during steam stripping or solvent extraction processes, preferably the cranberry seed oil is obtained by
cold pressing, resulting in virgin (i.e. an oil produced by only physical or mechanical means) cranberry seed oil. In one embodiment, therefore, the cranberry seed oil may be a virgin cranberry seed oil.
For example, the cranberry seed oil may be obtained by a process as described herein. The seeds removed from the fruit may be cold pressed and filtered. The filtration cake may be discarded and the filtrate (i.e. the virgin cranberry seed oil) may be used as is.
Cranberry extract and cranberry seed oil
As has been discussed above, both cranberry extracts and cranberry seed oils have been used in cosmetic products due to their beneficial properties when applied to the skin. However, no study evaluating the anti-inflammatory effect of cranberry extracts or cranberry seed oils has been undertaken to date.
It was surprisingly and unexpectedly observed that, by treating keratinocytes stressed with phorbol 12-myristate 13-acetate (PMA) with a combination of cranberry extracts and cranberry seed oils, the release of cytokine TNF-a was significantly reduced compared to treatment with only cranberry extract or cranberry seed oil independently. The effect of the combination of cranberry extracts and cranberry seed oils on the release of cytokine TNF-a was much higher than the effect expected by simply adding up the effects of the two independent components. Thus, a synergistic effect of the combination of cranberry extracts and cranberry seed oils can be clearly observed (see, e.g., example 3 below).
In one embodiment, the ratio between the cranberry extract and cranberry seed oil is between about 15:1 to about 1 :0.2. Preferably, the ratio between the cranberry extract and cranberry seed oil is between about 12:1 to about 1 :0.5. For example, the ratio between the cranberry extract and cranberry seed oil may be about 12:1 , 11 :1 , 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1 :1 , 1 :0.9, 1 :0.8, 1 :0.7, 1 :0.6 or 1 :0.5, in particular about 10:1 or about 1 :1.
Cosmetic Product
Another aspect of the present invention provides a cosmetic product comprising a cosmetic composition comprising cranberry extract in combination with cranberry seed oil as defined hereinbefore and a cosmetic base.
The cosmetic base may comprise any cosmetically acceptable excipient. A cosmetically acceptable excipient can be any excipient commonly used in the preparation of cosmetic preparations for use on the human skin or scalp. Suitable excipients include, but are not limited to, ingredients that can influence organoleptic properties and penetration of the skin, as well as the amount of time the active ingredient(s) remain active on the skin. More specifically, they include liquids, such as water, oils or surfactants, including those of petroleum, animal, plant or synthetic origin, such as and not restricted to, peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbates, sorbitan esters, ether sulfates, sulfates, betaines, glycosides, maltosides, fatty alcohols, nonoxynols, poloxamers, polyoxyethylenes, polyethylene glycols, dextrose, glycerol, digitonin, and the like, or combinations thereof.
The formulation for topical application to the skin may take any physical form. For instance, the cosmetic product may be in the form of a liposome, mixed liposomes, oleosomes, niosomes, ethosomes, milliparticles, microparticles, nanoparticles and solid-lipid nanoparticles, vesicles, micelles, mixed micelles of surfactants, surfactant-phospholipid mixed micelles, millispheres, microspheres and nanospheres, lipospheres, millicapsules, microcapsules and nanocapsules, as well as microemulsions and nanoemulsions, which can be added to achieve a greater penetration of the cosmetic composition as defined herein.
The cosmetic product may be produced in any solid, liquid, or semi-solid form useful for application to the skin topically or by transdermal application. Thus, these preparations of topical or transdermal application include, but are not restricted to, creams, multiple emulsions, such as and not restricted to, oil and/or silicone in water emulsions, water-in-oil and/or silicone emulsions, water/oil/water or water/silicone/water type emulsions, and oil/water/oil or silicone/water/silicone type emulsions, micro-emulsions, emulsions and/or solutions, liquid crystals, anhydrous compositions, aqueous dispersions, oils, milks, balsams, foams, aqueous or oily lotions, aqueous or oily gels, cream, hydro-alcoholic solutions, hydro-glycolic solutions, hydrogels, liniments, sera, soaps, face masks, serums, polysaccharide films, ointments, mousses, pomades, pastes, powders, bars, pencils and sprays or aerosols (sprays), including leave-on and rinse-off formulations.
The cosmetic product of the present invention may also be any product typically used for hair care, including but not limited to a shampoo, conditioner, spray, treatment, mask, strengthened preshampoo, lotion, serum, cream, foam, mousse, and gel. Particularly preferably, the cosmetic product is a shampoo, anti-frizz hair spray, beauty hair mask, hair shininess serum, hair
conditioner, hair strengthener pre-shampoo, or hair protection lotion. Both leave-on and rinse-off product types are suitable.
The cosmetic product according to the present invention may further comprise one or more materials selected from the group consisting of carriers, solvents, surfactants, thickeners, styling polymers, anti-dandruff actives, antimicrobial materials, skin and scalp actives, vitamins, salts, buffers, hair growth agents, conditioning materials, hair-fixative polymers, fragrances, colorings/colorants, dyes, pigments, opacifiers, pearlescent aids, oils, waxes, preservatives, sensates, sunscreens, medicinal agents, antifoaming agents, antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, film formers or materials, pH adjusters, propellants, oxidizing agents, and reducing agents.
The cosmetic product of the present invention may be produced in any form typically used for skin or scalp care, including but not limited to a cream, a lotion, a spray, a gel, a foam a stick, a shampoo, a conditioner or a mousse, preferably a cream or a gel.
The cosmetic compositions and products of the present invention can additionally further comprise any suitable optional ingredients as desired. Such optional ingredients should be physically and chemically compatible with the essential components of the cosmetic composition or cosmetic product, and should not otherwise unduly impair stability, aesthetics or performance. The CTFA Cosmetic Ingredient Handbook, Tenth Edition (published by the Cosmetic, Toiletry, and Fragrance Association, Inc., Washington D.C.) (2004) describes a wide variety of non-limiting materials that can be added to the compositions and products of the present invention.
The concentration of the cranberry extract in a topical formulation of a cosmetic composition can be up to about 30% w/w. In one embodiment, the cosmetic product comprises about 0.5% to about 30%, optionally about 1 % to about 25%, optionally about 5% to about 15% w/w of cranberry extract.
In one embodiment, the cranberry extract may be provided in powder form and may be mixed with a solvent such as water, ethanol/water or glycerine, before incorporation in a cosmetic product.
The concentration of the cranberry seed oil in a topical formulation of a cosmetic product can be up to about 10% w/w. In one embodiment, the cosmetic product comprises about 0.05% to about 10%, optionally about 0.5% to about 5%, optionally about 1 % to about 3% w/w of cranberry seed oil.
Methods of use
The invention further provides a method for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, comprising topically applying to the skin or the scalp a composition comprising cranberry extract in combination with cranberry seed oil or a cosmetic product comprising a composition comprising cranberry extract in combination with cranberry seed oil as defined hereinbefore.
In particular, the invention provides a cosmetic method for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, i.e. a non-therapeutic method.
In one embodiment, the inflammation of the human skin or the human scalp may be caused by an infection, by an allergic reaction or by exposure to UV radiation.
In one embodiment, the inflammation of the human skin may be selected from the group consisting of sensitive skin, irritated skin, atopic dermatitis, rosacea, eczema and psoriasis.
In one embodiment, the inflammation of the human scalp may be selected from the group consisting of dermatitis, such as irritated skin due to dryness, itchy scalp, seborrhoeic dermatitis and contact dermatitis, scalp folliculitis and psoriasis of the scalp.
Non-limiting examples of symptoms of inflammation include redness, breakouts, acne, blemishes, rosacea, dark spots, hyperpigmentation, eczema, itching, or swelling of the skin and flakiness, swelling or redness of the scalp.
In yet another aspect, use of a composition comprising cranberry extract in combination with cranberry seed oil or a cosmetic product comprising a composition comprising cranberry extract in combination with cranberry seed oil as defined hereinbefore in alleviating or removing the symptoms of inflammation of the human skin or the human scalp is provided.
In particular, the invention provides a cosmetic use for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, i.e. a non-therapeutic use.
The present invention is further illustrated by means of the following non-limiting examples:
extract
The cranberry fruit may be ground, extracted with a mixture of water and ethanol and filtered. The filter cake may be discarded and the filtrate may undergo concentration/desolventation in order to
obtain a native extract of cranberry. The resulting native extract is further subjected to separation, purification and further formulation by mixing with magnesium hydroxide and tricalcium phosphate. The mixture may be dried by spray drying and, optionally, it may further undergo sieving.
For example, 134 kg of cranberries were ground and extracted with 80 kg of water. The liquid was separated from the solid mass, concentrated and subjected to further processing, comprising the step of mixing with magnesium hydroxide (8 kg) and tricalcium phosphate (1 Kg). 92 kg of cranberry extract with 30% w/w organic acids was obtained.
Example 2: Process of production of a cranberry seed oil
The seeds removed from the fruit may be cold pressed and filtered. The filtration cake may be discarded and the filtrate (i.e. the virgin cranberry seed oil) may be used as is. For example, 1 .667 kg of cranberries were squeezed and sliced to remove the seeds. The seeds (about 17 g) were collected, dried and cold pressed to obtain about 1 g of cranberry seed oil.
Example 3: Anti-inflammatory effect of a cranberry extract, a cranberry seed oil and combinations of a cranberry extract and a cranberry seed oil
The effect of a cranberry extract, a cranberry seed oil and combinations of a cranberry extract and a cranberry seed oil on the anti-inflammatory activity of keratinocytes stressed with PMA was evaluated by comparing the decrease of the cytokine TNF-a release of Normal Human Epidermal Keratinocytes (NHEKs) treated with the cranberry products and stressed with PMA (Phorbol 12- myristate 13-acetate) with the TNF-a release of untreated NHEKs stressed with PMA.
3.1. Cell culture and treatment
The cell culture was done on primary cells isolated from fresh biopsies. NHEKs were seeded in a type I collagen pre-coated 24 wells-plate at 30 000 cells per well in triplicate.
The cells were incubated 24 hours in complete medium (Epilife medium supplemented with HKGS, Gibco) and 1 % of antibiotics (Sigma-Aldrich) at 37 °C with 5% CO2.
At the end of the incubation, the cells were rinsed twice with phosphate buffered saline (PBS, Gibco) and pre-incubated with active components for 24 hours in Epilife complete medium (Epilife + Human keratinocyte growth supplements (HKGS) supplements, Gibco) without Hydrocortisone and 1 % of antibiotics at 37 °C with 5% CO2.
After 24 hours of pre-incubation, the cells were stressed with PMA (Phorbol 12-myristate 13- acetate, Sigma) at 1 ng/mL and incubated for 24 hours at 37 °C with 5% CO2.
The compounds used for the comparison are as shown in Table 1. Non-treated cells were used as a blank. Cells treated with a known anti-inflammatory (dexamethasone) were used as a reference.
Table 1 : Compounds and cranberry products tested for their anti-inflammatory effect on NHEKs
Skin cells untreated and cultivated with medium were used as negative control.
At the end of the culture, the cell media were collected and centrifuged at 2000 g for 10 minutes at 4 °C to eliminate dead cells. The media were stored at -20 °C.
A MTT assay was performed to evaluate treatments toxicity and for the normalisation of TNF-a quantification.
The assay was done in quadruplicate.
3.2. MTT assay MTT solution (Sigma) diluted at 1 mg/mL in basal medium was added to each well and incubated for 3 hours at 37 °C, 5% CO2. Then, the medium was removed and 300 pL of dimethyl sulfoxide (DMSO, Sigma) was added into each well to dissolve the formazan crystals. Homogenization was
done under orbital agitation for few minutes. The optical density was measured at a wavelength of 560 nm.
3.3. TNF-a quantification
The TNF-a quantification was realized with the Human TNF-alpha Quantikine ELISA kit (DTA00D, R&D Systems).
The samples and the standard range were incubated for 2 hours in 96-wells plate pre-coated with a monoclonal antibody specific for human TNF-a in presence of the Assay Diluent RD1 F. After four washes with wash buffer provided by the supplier, a polyclonal antibody specific for human TNF-a conjugated to horseradish peroxidase enzyme (HRP) was incubated for 2 hours under orbital agitation. Following 4 washes, a substrate solution was added to the wells for 30 minutes in the dark. The catalysis of this substrate by HRP generates blue colour in proportion to the amount of TNF-a bound in the initial step. The colour development was stopped by a Stop solution and changed to yellow colour. The optical density was measured at 450 nm and 540 nm with a microplate reader (TECAN SPARK® 10M).
The Four Parameter Logistic Curve analysis was performed via the Myassays website (http://myassays.com) after subtraction of optical density at 450 nm by optical density at 540 nm.
The quantification was carried out in duplicate.
The quantification was normalized with the optical density measured via the MTT assay.
3.4. Statistical analysis
A Shapiro-Wilk normality test revealed that the samples did not follow the Gaussian Law. Consequently, a non-parametric statistical analysis was performed with Kruskal-Wallis ANOVA followed by Mann Whitney U test. A result was considered significant with p<0.1 (marked with #), p<0.05 (marked with *), p<0.01 (marked with **) and p<0.001 (marked with ***).
Figure 1 shows the results of the non-parametric statistical analysis using the Mann Whitney test for samples 1 to 7 in Table 1 .
The quantification demonstrated that, after 24 hours of the PMA stress (entry 1 in Table 1), the keratinocytes significantly released cytokine TNF-a. The pre-treatment with dexamethasone (1
pM, entry 2) significantly reduced the release of the cytokine by 46%***. These results confirmed the responsiveness of the model.
In the same conditions, the cranberry extract at 0.5 mg/mL (entry 3), the cranberry seed oil at 0.05% v/v (entry 4) and 0.005% v/v (entry 5) significantly reduced the TNF-a release by 16%*, 34%*** and 32%***, respectively, compared to the sample of entry 1 .
In the presence of a combination of cranberry extract at 0.5 mg/mL and cranberry seed oil at 0.05% v/v (i.e. a ratio of 1 :1 , entry 4), the decrease of TNF-a release was significantly higher (75%***). The reduction was significantly better than what would have been expected by adding up the reduction due to each component individually. In the presence of a combination of cranberry extract at 0.5 mg/mL and cranberry seed oil at 0.005% v/v (i.e. a ratio of 10:1 , entry 6), the decrease of TNF-a release of 61 %*** was significant (p<0.001). The decrease was higher than what would have been expected by simply adding up the reduction due to each component individually.
Therefore, it has been shown that a combination of cranberry extract and cranberry seed oil has synergistic anti-inflammatory capability compared to each of the cranberry extract and cranberry seed oil independently.
Claims
1. Cosmetic composition for topical use, comprising cranberry extract in combination with cranberry seed oil.
2. The cosmetic composition according to claim 1 , wherein the cranberry extract is a hydrophilic extract.
3. The cosmetic composition according to claim 1 or claim 2, wherein the cranberry extract contains more than about 30% w/w organic acids.
4. The cosmetic composition according to any one of the preceding claims, wherein the cranberry extract further comprises an additive.
5. The cosmetic composition according to claim 4, wherein the additive comprises magnesium hydroxide and/or tricalcium phosphate.
6. The cosmetic composition according to claim 5, comprising about 5% to about 10% w/w magnesium hydroxide and/or less than about 1 % w/w of tricalcium phosphate.
7. The cosmetic composition according to any one of the preceding claims, wherein the cranberry seed oil is a virgin cranberry seed oil.
8. The cosmetic composition according to any one of the preceding claims, wherein the cranberry extract and the cranberry seed oil are in a ratio of between about 15:1 to about 1 :0.5.
9. A cosmetic product comprising the cosmetic composition according to any one of claims 1 to 8 and a cosmetically acceptable base.
10. The cosmetic product according to claim 9, wherein the product is provided as a cream, a lotion, a spray, a gel, a foam, a stick, a shampoo, a conditioner or a mousse.
11. The cosmetic product according to claim 9 or claim 10, wherein the cosmetic product comprises about 0.5% to about 30% w/w, preferably about 1 % to about 25% w/w, most preferably about 5% to about 15% w/w, of cranberry extract and about 0.05% to about 10% w/w, preferably about 0.5% to about 5% w/w, most preferably about 1% to about 3% w/w cranberry seed oil.
A method for alleviating or removing the symptoms of inflammation of the human skin or the human scalp, comprising topically applying to the skin or the scalp the cosmetic composition according to any one of claims 1 to 8 or the cosmetic product according to any one of claims 9 to 11 . The method of claim 12, wherein the inflammation of the human skin or the human scalp is caused by an infection, by an allergic reaction or by exposure to UV radiation. The method of claim 12 orclaim 13, wherein the inflammation of the human skin is selected from the group consisting of sensitive skin, irritated skin, atopic dermatitis, rosacea, eczema and psoriasis. The method of claim 12 or claim 13, wherein the inflammation of the human scalp is selected from the group consisting of dermatitis, such as irritated skin due to dryness, itchy scalp, seborrhoeic dermatitis and contact dermatitis, scalp folliculitis and psoriasis of the scalp. Use of the cosmetic composition according to any one of claims 1 to 8 or the cosmetic product according to any one of claims 9 to 11 in alleviating or removing the symptoms of inflammation of the human skin or the human scalp.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2114116.3A GB202114116D0 (en) | 2021-10-01 | 2021-10-01 | Cosmetic composition |
| PCT/EP2022/077096 WO2023052491A1 (en) | 2021-10-01 | 2022-09-29 | Cosmetic composition comprising cranberry extract and cranberry seed oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4408528A1 true EP4408528A1 (en) | 2024-08-07 |
Family
ID=78497849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22799871.3A Pending EP4408528A1 (en) | 2021-10-01 | 2022-09-29 | Cosmetic composition comprising cranberry extract and cranberry seed oil |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250000785A1 (en) |
| EP (1) | EP4408528A1 (en) |
| JP (1) | JP2024536276A (en) |
| KR (1) | KR20240073095A (en) |
| CN (1) | CN118159251A (en) |
| GB (1) | GB202114116D0 (en) |
| WO (1) | WO2023052491A1 (en) |
| ZA (1) | ZA202403367B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008500027A (en) * | 2004-05-03 | 2008-01-10 | ノーザン ライツ フード プロセシング，エルエルシー | Berry oil and products |
-
2021
- 2021-10-01 GB GBGB2114116.3A patent/GB202114116D0/en not_active Ceased
-
2022
- 2022-09-29 WO PCT/EP2022/077096 patent/WO2023052491A1/en not_active Ceased
- 2022-09-29 KR KR1020247014303A patent/KR20240073095A/en active Pending
- 2022-09-29 CN CN202280066216.0A patent/CN118159251A/en active Pending
- 2022-09-29 US US18/695,696 patent/US20250000785A1/en active Pending
- 2022-09-29 JP JP2024519845A patent/JP2024536276A/en active Pending
- 2022-09-29 EP EP22799871.3A patent/EP4408528A1/en active Pending
-
2024
- 2024-04-30 ZA ZA2024/03367A patent/ZA202403367B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118159251A (en) | 2024-06-07 |
| JP2024536276A (en) | 2024-10-04 |
| GB202114116D0 (en) | 2021-11-17 |
| US20250000785A1 (en) | 2025-01-02 |
| KR20240073095A (en) | 2024-05-24 |
| WO2023052491A1 (en) | 2023-04-06 |
| ZA202403367B (en) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nizioł‐Łukaszewska et al. | Saponins as natural raw materials for increasing the safety of bodywash cosmetic use | |
| JP6054700B2 (en) | Desugaring agent and external preparation for skin | |
| JP7758679B2 (en) | Method for obtaining an aqueous extract of lavender, compositions containing such extracts, and cosmetic uses thereof | |
| WO2012085224A1 (en) | Avocado flesh and/or skin extract rich in polyphenols and cosmetic, dermatological and nutraceutical compositions comprising same | |
| JP2023549283A (en) | Anti-aging and antioxidant cosmetic composition containing broccoli exosomes as an active ingredient, and functional cosmetics containing the same | |
| CN107412031B (en) | Skin external composition containing hesperetin | |
| EP4099976B1 (en) | Murraya koenigii extract and use thereof in cosmetics | |
| KR102400179B1 (en) | Cosmetic composition antimicroboal, antioxidation, whitening or anti-inflammation comprising artemisia capillaris thunberg and olive extract | |
| JPH08259431A (en) | Maillard reaction inhibitor and external preparation for skin containing the same | |
| JP6138317B2 (en) | Topical skin preparation | |
| US20250000785A1 (en) | Cosmetic composition comprising cranberry extract and cranberry seed oil | |
| JP6753602B2 (en) | Proton pump function accelerator | |
| KR102076722B1 (en) | Cosmetic Compositions With Prunus mume Extracts | |
| KR20190137329A (en) | Skin external application composition for anti-aging containing Phlox subulata extract | |
| KR102031663B1 (en) | Cosmetic composition and external composition comprising glucosyl withanolides for anti-inflammatory | |
| KR100860272B1 (en) | Extraction and purification method of active ingredient from Seonhakcho, and herbal composition for preventing and treating acne containing the extract | |
| US20250049698A1 (en) | Bioactive serum fractions from fresh rose flowers and methods for their preparation and uses | |
| JP2000198726A (en) | Agent for suppressing formation of lipid peroxide and composition containing the agent | |
| KR102286969B1 (en) | Composition for improving skin conditions comprising omega-7 derived from refined fish oil and red ginseng | |
| KR102366234B1 (en) | Skin wrinkle improvement effects of solvent extracts from Desmodium sequax Wall or fractions thereof | |
| WO2025038517A1 (en) | Chamomilla recutita (german chamomile) extract for improving the appearance of blemished skin | |
| KR20230116316A (en) | Cosmetic composition for promoting SVCT-1 and/or SVCT-2 expression comprising the extracts of Polygonum cuspidatum Root | |
| JP2000198740A (en) | Inhibitor of lipid peroxide production and composition containing the same | |
| WO2017217868A1 (en) | Water-dispersible propolis composition | |
| JP3597067B2 (en) | Antioxidant and composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240430 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) |